Literature DB >> 25272547

Honey in the treatment of Fournier's gangrene as an adjuvant: a cross sectional study.

Mohammad Haidari, Mohammad Reza Nazer, Mojtaba Ahmadinejad, Vahid Almasi, Manouchehr Shams Khorramabadi, Yadollah Pournia.   

Abstract

Fournier's gangrene is a progressive polymicrobial necrotising infection. The purpose of this study was to assess the outcome of Fournier's gangrene infection in patients who received topical honey with their therapeutic regimens. The cross-sectional study included 17 patients with Fournier's gangrene. Under spinal anaesthesia, the necrotic areas were debrided. In the first week, every day, the wounds were cleansed with Betadine, normal saline, and 2% oxygenated water, then 30-50cc of honey was used after the wounds were dried. The wounds were then dressed. This method of dressing was taught to the patients' attendants. The granulation tissues, generally bright pink, were observed on the 10th day. Four (23.5%) patients underwent colostomy and 1 (5.9%) died. All the patients were discharged two weeks after the initial debridement. Compared with other studies, honey reduced the healing and hospitalisation time as well as additional costs.

Entities:  

Mesh:

Year:  2014        PMID: 25272547

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  3 in total

1.  Honey: A Therapeutic Agent for Disorders of the Skin.

Authors:  Pauline McLoone; Afolabi Oluwadun; Mary Warnock; Lorna Fyfe
Journal:  Cent Asian J Glob Health       Date:  2016-08-04

Review 2.  Practical Review of the Current Management of Fournier's Gangrene.

Authors:  Maria T Huayllani; Amandip S Cheema; Matthew J McGuire; Jeffrey E Janis
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-03-14

3.  Fournier's gangrene: Causes, presentation and survival of sixty-five patients.

Authors:  Kerem Taken; Mehmet Resit Oncu; Muslum Ergun; Recep Eryilmaz; Canser Yilmaz Demir; Murat Demir; Mustafa Gunes
Journal:  Pak J Med Sci       Date:  2016 May-Jun       Impact factor: 1.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.